Enterprise Value
2.687B
Cash
350.4M
Avg Qtr Burn
-27.81M
Short % of Float
5.26%
Insider Ownership
15.03%
Institutional Own.
83.10%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VYJUVEKTM (B-VEC) (Topical Beremagene Geperpavec) Details Skin disease/disorder, Dystrophic epidermolysis bullosa, Epidermolysis bullosa | Approved Quarterly sales | |
KB105 Details Autosomal recessive congenital ichthyosis , Skin disease/disorder | Phase 2 Interim update | |
KB301 Details Wrinkles | Phase 1 Data readout |